Pictet North America Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Pictet North America Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-928	Closed	-$815K	–	148
2023 Q4	$815K	Hold	928	–	–	0.11%	88
2023 Q3	$764K	Hold	928	–	–	0.11%	91
2023 Q2	$667K	Hold	928	–	–	0.09%	95
2023 Q1	$763K	Hold	928	–	–	0.12%	86
2022 Q4	$670K	Hold	928	–	–	0.12%	84
2022 Q3	$639K	Hold	928	–	–	0.1%	91
2022 Q2	$549K	Hold	928	–	–	0.07%	102
2022 Q1	$648K	Hold	928	–	–	0.08%	93
2021 Q4	$586K	Hold	928	–	–	0.06%	95
2021 Q3	$562K	Hold	928	–	–	0.06%	96
2021 Q2	$518K	Hold	928	–	–	0.05%	100
2021 Q1	$439K	Hold	928	–	–	0.05%	100
2020 Q4	$448K	Hold	928	–	–	0.06%	105
2020 Q3	$519K	Hold	928	–	–	0.07%	100
2020 Q2	$579K	Hold	928	–	–	0.08%	95
2020 Q1	$453K	Hold	928	–	–	0.08%	108
2019 Q4	$348K	Buy	+928	New	+$312K	0.04%	128

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pictet North America Advisors's REGN Position: Q1 2024 in Review

Pictet North America Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 928 shares — an estimated $815K sold.

Pictet North America Advisors first reported a position in REGN in Q4 2019 and held it in 17 quarters. The position peaked at $815K in Q4 2023. 1,310 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Pictet North America Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Pictet North America Advisors sold 928 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $815K.
Pictet North America Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 17 quarters.
Pictet North America Advisors's Regeneron Pharmaceuticals position peaked at $815K in Q4 2023.
1,310 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Pictet North America Advisors's 13F filing for Q1 2024, filed 3 May 2024.